Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Down 96.2% in March

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 159,600 shares, a decrease of 96.2% from the February 28th total of 4,160,000 shares. Approximately 14.9% of the shares of the company are sold short. Based on an average trading volume of 936,100 shares, the short-interest ratio is presently 0.2 days.

Hepion Pharmaceuticals Stock Performance

Hepion Pharmaceuticals stock traded down $0.09 during mid-day trading on Thursday, reaching $0.60. 467,484 shares of the company were exchanged, compared to its average volume of 256,875. Hepion Pharmaceuticals has a twelve month low of $0.55 and a twelve month high of $145.00. The firm’s 50-day simple moving average is $7.46 and its two-hundred day simple moving average is $22.90. The firm has a market cap of $82,705.00, a PE ratio of -0.14 and a beta of 1.62.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP acquired a new stake in shares of Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals as of its most recent SEC filing. 17.24% of the stock is currently owned by hedge funds and other institutional investors.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.